Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.

Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949.

View in: PubMed

subject areas

Adalimumab
Adult
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Anxiety
Cross-Over Studies
Depression
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Female
Humans
Incidence
Linear Models
Male
Middle Aged
Multivariate Analysis
Neuropsychological Tests
Prognosis
Psoriasis
Risk Assessment
Severity of Illness Index
Treatment Outcome
Young Adult

authors with profiles

Kenneth Gordon